Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested an experimental drug called RO7759065, given alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was termin…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Lung scarring drug trial halted midway – what we know
Disease control TerminatedThis study tested a drug called vixarelimab to see if it could improve lung function in people with two types of lung scarring: idiopathic pulmonary fibrosis (IPF) and lung scarring linked to scleroderma (SSc-ILD). About 286 adults took either the drug or a placebo for 52 weeks, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Kidney shield drug trial halted early – what it means for heart surgery patients
Prevention TerminatedThis study tested whether the drug GDC-8264 could prevent acute kidney injury and serious kidney problems in people having heart surgery. About 67 participants at moderate to high risk were enrolled, but the trial was stopped early. The goal was to see if the drug worked better t…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Prevention
Last updated May 06, 2026 16:02 UTC